MRSN

Mersana Therapeutics, Inc.

2.10 USD
+0.02 (+0.96%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mersana Therapeutics, Inc. stock is down -5.41% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 July’s closed higher than June.

About Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.